OBJECTIVES: The aim of this study was to detect anti-topoisomerase I (anti-topo I) autoantibodies, which are known to be limited in systemic sclerosis patients, in silicosis patients with no clinical symptoms of autoimmune disease. METHODS: Serum anti-topo I autoantibodies were detected using ELISA. Differences in clinical parameters between patients with and without anti-topo I autoantibodies were analyzed. RESULTS: Seven of 69 patients had anti-topo I autoantibodies. These 7 patients showed elevated PaCO(2) values (P=0.0212), and inverse correlations between serum soluble Fas levels and PaCO(2) values were found. CONCLUSION: Anti-topo I autoantibodies were detected in 10.1% of silicosis patients without any clinical symptoms of autoimmune disease. The findings here suggest that the genesis of anti-topo I autoantibodies might be related to pulmonary involvement or lung fibrosis associated with progression of silicosis.
OBJECTIVES: The aim of this study was to detect anti-topoisomerase I (anti-topo I) autoantibodies, which are known to be limited in systemic sclerosispatients, in silicosispatients with no clinical symptoms of autoimmune disease. METHODS: Serum anti-topo I autoantibodies were detected using ELISA. Differences in clinical parameters between patients with and without anti-topo I autoantibodies were analyzed. RESULTS: Seven of 69 patients had anti-topo I autoantibodies. These 7 patients showed elevated PaCO(2) values (P=0.0212), and inverse correlations between serum soluble Fas levels and PaCO(2) values were found. CONCLUSION: Anti-topo I autoantibodies were detected in 10.1% of silicosispatients without any clinical symptoms of autoimmune disease. The findings here suggest that the genesis of anti-topo I autoantibodies might be related to pulmonary involvement or lung fibrosis associated with progression of silicosis.
Entities:
Keywords:
apoptosis; autoantibody; autoimmunity; silicosis; topoisomerase I
Authors: T Otsuki; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; H Ueki; M Kusaka; S Kita; A Ueki Journal: Clin Exp Immunol Date: 2000-02 Impact factor: 4.330
Authors: T Otsuki; K Ichihara; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; M Kusaka; S Kita; A Ueki Journal: Int J Mol Med Date: 1999-10 Impact factor: 4.101
Authors: T Hasunuma; N Kayagaki; H Asahara; S Motokawa; T Kobata; H Yagita; H Aono; T Sumida; K Okumura; K Nishioka Journal: Arthritis Rheum Date: 1997-01
Authors: A Tomokuni; T Aikoh; T Matsuki; Y Isozaki; T Otsuki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki Journal: Clin Exp Immunol Date: 1997-11 Impact factor: 4.330